BerGenBio taps into Piramal’s platform to develop leukemia treatment

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/undefined)
(Image: Getty/undefined)

Related tags: Piramal, CDMO, Leukemia, Contract manufacturing

Piramal to support the development of BerGenBio’s treatment for acute myeloid leukemia, after the US FDA granted the candidate fast track designation.

BerGenBio’s bemcentinib is a selective AXL inhibitor, currently in Phase II clinical trials as a combination and single agent therapy for lung cancer and leukemia.  

The US Food and Drug Administration (FDA) recently granted the candidate fast track designation for the treatment of elderly patients with acute myeloid leukemia (AML) whose disease has relapsed, an indication for which there are no approved drugs available to date.

Following the designation, the drug developer announced its plans to outsource further development and manufacturing operations to Piramal, and the latter’s ‘Xcelerate Integrated Solutions’ platform, which, according to BerGenBio’s CEO, Richard Godfrey, represents an ‘ideal’ solution.

According to Piramal, this specific service was chosen in order to meet the timelines required for fast track development.

However, Piramal’s program includes a long manufacturing journey, with the required intermediates sourced in India; subsequently, the pilot process development and validation takes place in North America; and, ultimately, the formulation development will occur in Europe.

The Xcelerate program has been successfully applied to more than eighty programs to date, according to Piramal, with the company stating that it is preferable for clients due to its streamlined services, “managed by a single point of contact who expedites the exchange of information.”

Upon the potential regulatory approval of the candidate, Piramal will also provide the commercial manufacture of the final drug product.

Financial terms of the partnership were not disclosed.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Related suppliers

Follow us


View more